The novel smallmolecule anticancer drug candidate licensed to SynCore Biotechnology has been approved for the Phase II clinical trial by TFDA and US FDA
NHRI licensed “the novel small-molecule anticancer…
分類: News & Events
The National Health Research Institutes (NHRI) and Molecular Targeting Technologies Inc. co-published the results of the cooperation on new anti-cancer therapeutics at the American Association for Cancer Research (AACR) meeting 2015
The National Health Research Institutes (NHRI) and…
The novel anti-diabetic drug candidate DBPR108 developed in relays by IBPR with the collaborator received the approval to implement Phase I clinical trial from China Food and Drug Administration (CFDA).
IBPR has implemented the project, pre-clinical and…
The National Health Research Institutes (NHRI) and Molecular Targeting Technologies Inc. co-published the results of the cooperation on new anti-cancer therapeutics at the American Association for Cancer Research (AACR) meeting 2015
The National Health Research Institutes (NHRI) and…
The novel anti-diabetic drug candidate DBPR108 developed in relays by IBPR with the collaborator received the approval to implement Phase I clinical trial from China Food and Drug Administration (CFDA).
IBPR has implemented the project, pre-clinical and…